冠心病患者血浆巨噬细胞移动抑制因子、基质金属蛋白酶-9测定的临床意义

目的观察冠心病患者巨噬细胞移动抑制因子（MIF）和基质金属蛋白酶-9（MMP-9）血浆水平的变化，探讨其在不同类型冠心病中的临床意义。方法我院心内科住院患者97例，根据冠状动脉造影结果分为对照组24例和冠心病组73例，冠心病组根据临床诊断分为稳定型心绞痛（SAP）组33例，急性冠脉综合征（ACS）组4JD例，用酶联免疫吸附法（ELISA）检测动脉血浆MIF和MMP-9水平。结果ACS组MIF血浆水平（17．96±1．58）μg／L，高于对照组（9．62±1．70，P〈0．01）及SAP组（10．39±1．25，P〈0．01），对照组与SAP组差异无统计学意义（P〉0．05）。ACS组MMP-9血浆水平（51．18±2．26）μL，高于对照组（26．74±2．99，P〈0．01）及SAP组（28．06±3．01，P〈0．01），对照组与SAP组差异无统计学意义（P〉0．05）。结论患者血浆MIF、MMP-9可能对冠状动脉粥样硬化斑块的形成及重塑有促进作用，对冠心病的发展有一定的预测价值。

Clinical significance of plasma macrophage migration inhibitory factor,matrix metalloproteinase-9 levels in patients with coronary heart disease

Objective To investigate the changes of plasma macrophage migration inhibitory factor （MIF） and matrix metalloproteinase-9 （MMP-9） levels in coronary heart disease （CHD） patient, and assess the value of MIF and MMP-9 in predicting different types of CHD. Methods Patient were divided into normal controls （n=24） and CHD （n=73） according to the coronary angiography （CAG）, CHD group divided into stable angina pectori （SAP, n=33） and acute coronary syndrome （ACS, n=40） according to the clinical symptom. Enzyme linked immunosorbent assay was used to measure the plasma MIF and MMP-9 concentrations. Results The plasma level of MIF in patients with ACS （17.96±1.58）μg/L were higher than it in control group （9.62±1.70,P〈0.01） an SAP group （ 10.39±1.25, P〈0.01 ）. Compared with control, the level of MIF in patients with SAP had no statistic difference（P〉0.05）. The plasma level of MMP-9 in patients with ACS（51.18±2.26）μg/L were higher than it in control group（26.74±2.99,P〈0.01 ） an SAP group（28.06±3.01, P〈0.01 ）. Compared with control,the level of MMP-9 in patients with SAP had no statistic difference （P〉0.05）. Conclusion MIF and MMP-9 have promotion to atherosclerotic plaque formation, and may serve as good indicators for the prediction of CHD.